Outlook Therapeutics Appoints Surendra Sharma, MD, and Glen Olsheim to Leadership Positions

Outlook Therapeutics announced the appointments of Surendra Sharma, MD, as Senior Vice President, Medical Affairs, and Glen Olsheim as Executive Director, Commercial Excellence.

“Outlook Therapeutics is very happy to welcome Surendra and Glen to our growing executive leadership team. Their respective backgrounds in directing the medical affairs of an ophthalmic portfolio and of driving the successful launch and commercialization of ophthalmic products will be tremendously valuable as we move toward the commercial launch of ONS-5010 ophthalmic bevacizumab, pending its approval by the U.S. FDA,” Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, said in a company news release.

Dr. Sharma has more than 15 years of experience in the pharmaceutical and biotechnology industries, leading corporate alliances among R&D, commercial, marketing and business stakeholders. Most recently, he was Senior Medical Director, Cornea, Dry Eye and Retina, Global Medical Affairs at Santen Pharmaceuticals. Over the course of his career at companies including Spark Therapeutics, Inc., Biogen Inc., Alcon Laboratories, Inc. and Regeneron Pharmaceuticals, Inc., he led global scientific communications strategies designed to align and meet the needs of key stakeholders in the North American and global markets. 

Mr. Olsheim brings to Outlook Therapeutics more than 15 years of product commercialization experience in ophthalmology. Prior to joining Outlook Therapeutics, in his role as the VP of Business and New Product Development at Fagron Sterile Services, he focused on driving revenue, profit and value in repackaging IV bevacizumab for ophthalmic use in retina indications.